← Leaderboards
Vishal Patel
Ut Southwestern Medical Center
$6,555,091
Attributed
$6,555,091
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $973.5K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,555,091 · 4
By mechanism
R01$5,668,316 · 2
K08$727,775 · 1
R03$159,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Ronak Lakhia$1,274,410
- Saikat Mukhopadhyay$5,068,868
Others in their field
Top investigators on “Cyst”
- Anirban Maitra · Johns Hopkins University$20,646,447
- Keri Hammel · The Emmes Company, Llc$18,651,231
- Jing Zhou · Massachusetts General Hospital$16,789,640
- L David Sibley · Washington University$16,276,257
- Bradley K. Yoder · University Of Alabama At Birmingham$15,926,453
- Stefan Somlo · Yale University$15,742,951
Research focus
CystPolycystic Kidney DiseasesMicrornasGeneticMessenger RnaAdultAffectNovel TherapeuticsCystic KidneyMouse ModelGrowthKidneyMediatingExhibitsAutosomal Dominant Polycystic KidneyPreventDesignCellsPathway InteractionsPharmaceutical PreparationsPathogenesisOligonucleotidesOverexpressionPathogenicity
Grant awards (20)
PKD1 derepression as a potential therapy for Polycystic Kidney Disease$545,651
R01 · FY2025 · DK · contact PI
PKD1 derepression as a potential therapy for Polycystic Kidney Disease$523,824
R01 · FY2024 · DK · contact PI
The impact of RNA chemical modifications on polycystic kidney disease progression$403,654
R01 · FY2024 · DK · contact PI
PKD1 derepression as a potential therapy for Polycystic Kidney Disease$545,651
R01 · FY2023 · DK · contact PI
The impact of RNA chemical modifications on polycystic kidney disease progression$424,176
R01 · FY2023 · DK · contact PI
PKD1 derepression as a potential therapy for Polycystic Kidney Disease$545,651
R01 · FY2022 · DK · contact PI
The impact of RNA chemical modifications on polycystic kidney disease progression$427,879
R01 · FY2022 · DK · contact PI
The impact of RNA chemical modifications on polycystic kidney disease progression$430,924
R01 · FY2021 · DK · contact PI
MicroRNAs: New Regulators of Disease Progression in Polycystic Kidney Disease$364,500
R01 · FY2019 · DK · contact PI
MicroRNAs: New Regulators of Disease Progression in Polycystic Kidney Disease$364,500
R01 · FY2018 · DK · contact PI
MicroRNAs: New Regulators of Disease Progression in Polycystic Kidney Disease$364,500
R01 · FY2017 · DK · contact PI
MicroRNAs: New Regulators of Disease Progression in Polycystic Kidney Disease$364,031
R01 · FY2016 · DK · contact PI
MicroRNAs: New Regulators of Disease Progression in Polycystic Kidney Disease$363,375
R01 · FY2015 · DK · contact PI
miRNA-based therapeutics in polycystic kidney disease$79,500
R03 · FY2014 · DK · contact PI
Role of microRNA in kidney development and pathogenesis of PKD$145,555
K08 · FY2013 · DK · contact PI
miRNA-based therapeutics in polycystic kidney disease$79,500
R03 · FY2013 · DK · contact PI
Role of microRNA in kidney development and pathogenesis of PKD$145,555
K08 · FY2012 · DK · contact PI
Role of microRNA in kidney development and pathogenesis of PKD$145,555
K08 · FY2011 · DK · contact PI
Role of microRNA in kidney development and pathogenesis of PKD$145,555
K08 · FY2010 · DK · contact PI
Role of microRNA in kidney development and pathogenesis of PKD$145,555
K08 · FY2009 · DK · contact PI